- Home
- Publications
- Publication Search
- Publication Details
Title
Cetuximab in the treatment of patients with colorectal cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 11, Issue 7, Pages 937-949
Publisher
Informa Healthcare
Online
2011-05-11
DOI
10.1517/14712598.2011.582464
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Efficacy of Panitumumab Therapy After Progression With Cetuximab: Experience at Two Institutions
- (2011) Muhammad Wasif Saif et al. Clinical Colorectal Cancer
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication
- (2010) Salvatore Siena et al. CANCER
- Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
- (2010) Sergio Rizzo et al. CANCER TREATMENT REVIEWS
- Clinical significance of tumor suppressor PTEN in colorectal carcinoma
- (2010) C.P. Hsu et al. EJSO
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study
- (2010) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66
- (2010) Steven R. Alberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
- (2010) Bryan T.J. Hennessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Does Sunscreen Prevent Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash? Results of a Placebo-Controlled Trial from the North Central Cancer Treatment Group (N05C4)
- (2010) A. Jatoi et al. ONCOLOGIST
- Declining Death Rates Reflect Progress against Cancer
- (2010) Ahmedin Jemal et al. PLoS One
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
- (2009) H. Prenen et al. CLINICAL CANCER RESEARCH
- Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience
- (2009) Derek G. Power et al. INVESTIGATIONAL NEW DRUGS
- PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
- (2009) Fotios Loupakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
- (2009) Pierre Laurent-Puig et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CAMutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
- (2009) Shuji Ogino et al. JOURNAL OF CLINICAL ONCOLOGY
- Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival
- (2009) David J. Gallagher et al. JOURNAL OF CLINICAL ONCOLOGY
- FDA narrows drug label usage
- (2009) Elie Dolgin NATURE
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil
- (2008) P. Pfeiffer et al. ANNALS OF ONCOLOGY
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- (2008) Astrid Lièvre et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR FISH in colorectal cancer: what is the current reality?
- (2008) Mauro Moroni et al. LANCET ONCOLOGY
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
- (2008) Christine H. Chung et al. NEW ENGLAND JOURNAL OF MEDICINE
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now